CLINICAL_TRIALS
trial_result
· 2018-06-19
Clinical Trial Update: A Study of LY2127399 in Participants With Systemic Lupus Erythematosus [Phase 3]
Summary
A Phase 3 trial evaluating LY2127399 (tabalumab) for systemic lupus erythematosus has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-06-19